Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Protagonist Therapeutics Inc before investing.

In this article, we go over a few key elements for understanding Protagonist Therapeutics Inc’s stock price such as:

• Protagonist Therapeutics Inc’s current stock price and volume
• Why Protagonist Therapeutics Inc’s stock price changed recently
• Upgrades and downgrades for PTGX from analysts
• PTGX’s stock price momentum as measured by its relative strength

About Protagonist Therapeutics Inc (PTGX)

Before we jump into Protagonist Therapeutics Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (a4ß7) specific integrin antagonist for inflammatory bowel disease (IBD).

Want to learn more about Protagonist Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc’s Stock Price as of Market Close

As of April 25, 2024, 4:00 PM, CST, Protagonist Therapeutics Inc’s stock price was $24.66.

Protagonist Therapeutics Inc is down 4.05% from its previous closing price of $25.70.

During the last market session, Protagonist Therapeutics Inc’s stock traded between $25.59 and $27.61. Currently, there are 60.43 million shares of Protagonist Therapeutics Inc stock available for purchase.

Unfortunately, Protagonist Therapeutics Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Protagonist Therapeutics Inc Stock Price History

Protagonist Therapeutics Inc’s (PTGX) price is currently down 14.76% so far this month.

During the month of April, Protagonist Therapeutics Inc’s stock price has reached a high of $29.21 and a low of $24.51.

Over the last year, Protagonist Therapeutics Inc has hit prices as high as $33.34 and as low as $13.72. Year to date, Protagonist Therapeutics Inc’s stock is up 126.03%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Protagonist Therapeutics Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2024, there was 1 analyst who downgraded Protagonist Therapeutics Inc’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Protagonist Therapeutics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Protagonist Therapeutics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Protagonist Therapeutics Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Protagonist Therapeutics Inc (PTGX) by visiting AAII Stock Evaluator.

Relative Price Strength of Protagonist Therapeutics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2024, Protagonist Therapeutics Inc has a weighted four-quarter relative price strength of 1.11%, which translates to a Momentum Score of 70 and is considered to be Strong.

Want to learn more about how Protagonist Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Protagonist Therapeutics Inc Stock Price: Bottom Line

As of April 25, 2024, Protagonist Therapeutics Inc’s stock price is $24.66, which is down 4.05% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Protagonist Therapeutics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.